Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06582602 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-2060 in Healthy Participants (MK-2060-016)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT06582602 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 23 participants.
The verdict
NCT06582602, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MK-2060
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-10-15 |
| Est. Completion | 2025-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06582602
The ClinicalTrials.gov registry entry for NCT06582602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06582602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06582602 about?
NCT06582602 is a clinical study titled "A Study of MK-2060 in Healthy Participants (MK-2060-016)". The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.
What is the current status of trial NCT06582602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2024-10-15. Estimated completion is 2025-04-18.
What interventions are being tested in trial NCT06582602?
The interventions under investigation include: Placebo (BIOLOGICAL), MK-2060 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06582602?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.